During a recent press conference addressing autism-related topics, federal health officials revealed promising research regarding leucovorin, a prescription vitamin generally used to treat cancer and anemia. Present at the event were FDA Commissioner Marty Makary, National Institutes of Health (NIH) Director Jay Bhattacharya, and Centers for Medicare and Medicaid Services Administrator Mehmet Oz. They discussed emerging studies that suggest leucovorin may be effective in treating children with autism spectrum disorder (ASD) focused particularly on speech deficits.
The U.S. Food and Drug Administration (FDA) plans to label leucovorin as a potential treatment for speech-related challenges associated with autism. This update will also allow state Medicaid programs to cover the medication for autism treatment, as outlined in a recent press release from the Department of Health and Human Services (HHS). In addition, the NIH is set to initiate new research initiatives to further explore leucovorin’s safety and effectiveness for children with ASD.
Leucovorin, which functions similarly to folic acid, assists in restoring folate levels in individuals who may struggle with its absorption. Katy Dubinsky, a pharmacist and CEO of a New York-based supplement company, explained that leucovorin is FDA-approved to mitigate the toxic effects of high-dose methotrexate in cancer treatments and to prevent certain types of folate-deficiency anemia. Although leucovorin is not officially prescribed for autism yet, anecdotal evidence from families suggests significant communication improvements in autistic children when used off-label.
Dr. Richard E. Frye, a behavioral child neurologist in Arizona, has investigated leucovorin as a potential treatment for autism spectrum disorder. His studies indicate that the drug significantly aids in language development, while also potentially enhancing social function, reducing repetitive behaviors, and improving attention skills. Despite these positive findings, Frye cautioned that the efficacy of leucovorin can vary, and some children may become overly hyperactive or show no response to the treatment, necessitating alternative therapies.
Experts emphasize the importance of consulting with health professionals before initiating treatment with leucovorin. While the safety of long-term use of folate has been established due to its history in food supplementation, it is critical for physicians to prescribe leucovorin appropriately, especially since it is typically administered in higher doses than standard vitamins.
Frye expressed hope for FDA approval of leucovorin for autism treatment, which could lead to broader prescription practices and standardized guidelines, increasing accessibility for families in need. Dubinsky echoed this sentiment, highlighting that insurance coverage and wider acceptance within the medical community could result from FDA endorsement.
Despite ongoing interest in leucovorin, experts warn against expecting it to be a standalone solution for autism. “There is no magic bullet for autism,” Frye said, noting that many children benefit from a combination of therapeutic approaches. Dr. Andy Shih from Autism Speaks commented on the variability of autism experiences among children, stressing the necessity for larger, controlled clinical trials to assess leucovorin’s overall safety and effectiveness.
Conclusively, while leucovorin represents a potential breakthrough in autism treatment, health professionals advise caution and collaboration with physicians before considering its off-label use. The hope is that ongoing research will affirm leucovorin’s role in enhancing the quality of life for children with ASD.
